| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GALNT14 |
| Uniprot No | Q96FL9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-552aa |
| 氨基酸序列 | MRRLTRRLVLPVFGVLWITVLLFFWVTKRKLEVPTGPEVQTPKPSDADWDDLWDQFDERRYLNAKKWRVGDDPYKLYAFNQRESERISSNRAIPDTRHLRCTLLVYCTDLPPTSIIITFHNEARSTLLRTIRSVLNRTPTHLIREIILVDDFSNDPDDCKQLIKLPKVKCLRNNERQGLVRSRIRGADIAQGTTLTFLDSHCEVNRDWLQPLLHRVKEDYTRVVCPVIDIINLDTFTYIESASELRGGFDWSLHFQWEQLSPEQKARRLDPTEPIRTPIIAGGLFVIDKAWFDYLGKYDMDMDIWGGENFEISFRVWMCGGSLEIVPCSRVGHVFRKKHPYVFPDGNANTYIKNTKRTAEVWMDEYKQYYYAARPFALERPFGNVESRLDLRKNLRCQSFKWYLENIYPELSIPKESSIQKGNIRQRQKCLESQRQNNQETPNLKLSPCAKVKGEDAKSQVWAFTYTQQILQEELCLSVITLFPGAPVVLVLCKNGDDRQQWTKTGSHIEHIASHLCLDTDMFGDGTENGKEIVVNPCESSLMSQHWDMVSS |
| 预测分子量 | 71.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GALNT14重组蛋白的3篇代表性文献摘要(基于公开研究归纳，非真实文献)：
---
1. **标题**：*Recombinant GALNT14 promotes hepatocellular carcinoma invasion by modulating O-glycosylation of EGFR*
**作者**：Wu X. et al.
**摘要**：研究报道了重组GALNT14蛋白在肝细胞癌中的促癌作用，发现其通过催化表皮生长因子受体(EGFR)的O-糖基化修饰，激活下游MAPK信号通路，从而增强肿瘤细胞侵袭能力。
2. **标题**：*Expression and enzymatic characterization of human GALNT14 recombinant protein in E. coli*
**作者**：Zhang Y. et al.
**摘要**：通过大肠杆菌系统成功表达并纯化具有活性的GALNT14重组蛋白，分析了其底物特异性及最适酶活条件，为开发糖基化相关癌症生物标志物检测工具奠定基础。
3. **标题**：*GALNT14 recombinant protein induces chemoresistance in gastric cancer via glycosylation-dependent CD44 clustering*
**作者**：Li J. et al.
**摘要**：研究发现重组GALNT14蛋白通过O-糖基化修饰CD44分子，促进肿瘤干细胞特性及化疗耐药性，提示靶向GALNT14可能逆转胃癌耐药表型。
---
(注：以上为模拟文献摘要，实际研究请参考PubMed/NCBI等数据库。)
GALNT14 (polypeptide N-acetylgalactosaminyltransferase 14) is a member of the GALNT enzyme family responsible for initiating mucin-type O-glycosylation, a post-translational modification critical for protein stability, cellular communication, and disease progression. This enzyme catalyzes the transfer of N-acetylgalactosamine (GalNAc) to serine/threonine residues on target proteins, influencing their interactions and functions. GALNT14 has garnered attention for its potential role in cancer biology, particularly in tumor metastasis and drug resistance. Dysregulation of GALNT14 expression has been observed in various cancers, including hepatocellular carcinoma, colorectal cancer, and lung cancer, suggesting its involvement in oncogenic pathways.
Recombinant GALNT14 protein is engineered to enable detailed biochemical and functional studies. Typically produced in mammalian or insect cell systems using recombinant DNA technology, it retains the enzyme’s catalytic activity and substrate specificity. The protein structure includes a conserved catalytic domain and variable regulatory regions, allowing researchers to explore its substrate preferences, enzymatic kinetics, and interactions with inhibitors or therapeutic agents. Recombinant GALNT14 is instrumental in high-throughput assays to identify O-glycosylation targets or screen potential modulators of its activity.
Clinically, GALNT14 expression has been proposed as a biomarker for predicting chemotherapy response in cancers like hepatocellular carcinoma. Studies also link its genetic variants to disease susceptibility and progression. By utilizing recombinant GALNT14. researchers aim to unravel its mechanistic contributions to pathologies and develop targeted therapies. This protein serves as a vital tool for advancing precision medicine and understanding the complex roles of O-glycosylation in health and disease.
×
